Lopez DS, Huang D, Tsilidis KK, et al. - In a large, nationally representative, commercially insured cohort, researchers explored the connection of prostate cancer (PCa) with testosterone therapy [TTh] (injection or gel) and different TTh doses, and ascertained if this connection varies by the presence of diabetes at baseline. Participants in the study were 189,491 men (aged 40 to 60 years) in the IBM MarketScan Commercial Database, which involved 1,424 patients with diagnosed PCa from 2011 to 2014. To compute HRs for patients with incident PCa, multivariable adjusted Cox proportional hazards models were used. The data presented in this work showed a 33% decreased association of PCa after comparing the highest category (> 12) of TTh injections with the lowest (1-2 injections) category. Overall, increased use of TTh is inversely linked to PCa, and only among nondiabetics, this remained important. These findings support further study to infer any health advantage from TTh in large, randomized, placebo-controlled trials.